Exhibit 10.42

PROJECT AGREEMENT No. 1

BETWEEN

VIROPHARMA INCORPORATED

AND

OSG NORWICH PHARMACEUTICALS, INC.

(Vancocin)



---

TABLE OF CONTENTS:



|                         |  |                                      |  |   
|------------------------ |  | ------------------------------------ |  | --
|PROJECT AGREEMENT        |  | 3                                   
|1.                       |  | Identification of Terms.             |  | 3 
|2.                       |  | Development Activities.              |  | 5 
|3.                       |  | Equipment Purchase.                  |  | 6 
|4.                       |  | Manufacture of Product.              |  | 7 
|5.                       |  | Manufacturing Price.                 |  | 9 
|6.                       |  | Shelf Life and Storage Requirements. |  | 11
|7.                       |  | Term.                                |  | 11
|8.                       |  | Entire Agreement.                    |  | 12
|9.                       |  | Amendment.                           |  | 12
|PRICE EXHIBIT            |  | 14                                  
|DEVELOPMENT PLAN EXHIBIT |  | 18                                  
|SCHEDULE OF EXCEPTIONS   |  | 21                                  
|MATERIALS EXHIBIT        |  | 22                                  



---

PROJECT AGREEMENT No. 1

VIROPHARMA INCORPORATED (ViroPharma) and OSG NORWICH PHARMACEUTICALS, INC. (OSG Norwich) are entering into this Project Agreement
No. 1 (Project Agreement) effective as of the 30thday of November 2005 (the Project
Agreement Effective Date).

ViroPharma and OSG Norwich agree that this Project Agreement is entered into pursuant to the Master
Agreement between ViroPharma and OSG Norwich dated as of December 1, 2005 (the Agreement). The project described herein shall be governed by the terms, conditions and obligations set forth in the Agreement and this Project
Agreement, and the terms of the Agreement are hereby incorporated into this Project Agreement by reference. Notwithstanding the incorporation by reference of the Agreement into this Project Agreement, in the event of conflict between the terms,
conditions and obligations of this Project Agreement and the Agreement, the terms, conditions and obligations of this Project Agreement shall govern. Capitalized terms not otherwise defined herein shall have the meaning given them in the Agreement.

In addition to the foregoing, the Parties hereby agree as follows:



| | 1. | Identification of Terms.
| | -- | ------------------------

For
purposes of this Project Agreement, the following terms defined in the Agreement shall be further defined as follows:



| | (a) | Active Pharmaceutical Ingredient. Active Pharmaceutical Ingredient or API shall mean bulk Vancomycin Hydrochloride.
| | --- | -----------------------------------------------------------------------------------------------------------------------



| | (b) | API Reimbursement Price. API Reimbursement Price, in U.S. dollars, is the average per batch of Product price paid by ViroPharma to a third party for API during
the Calendar Quarter in which the price is being calculated.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (c) | API Specifications. API Specifications shall mean the specifications for Active Pharmaceutical Ingredient set forth in the Quality Agreement.
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------



| | (d) | Commencement Date. Commencement Date shall mean the date, following the Regulatory Approval Date, upon which ViroPharma authorizes OSG Norwich to commence
Manufacture of the Product.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (e) | Commercial Manufacturing Initiation. Commercial Manufacturing Initiation shall mean the completion of Development Plan and the start of manufacturing Product by
OSG Norwich for commercial sale and shall commence following the Commencement Date on the date the first post-validation lot is milled upon the request and direction of ViroPharma.
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (f) | Development Plan. Development Plan shall mean the development plan attached hereto as the Development Plan Exhibit.
| | --- | ---------------------------------------------------------------------------------------------------------------------



-3-



---

| | (g) | Initial Term. Initial Term shall mean the period of time required to complete Development Activities and the first five (5) years after Commercial
Manufacturing Initiation.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (h) | Lilly. Lilly shall mean Eli Lilly and Company.
| | --- | ------------------------------------------------



| | (i) | Lilly Project Agreement. Lilly Project Agreement shall mean that certain Project Agreement by and between Eli Lilly and Company and OSG Norwich dated
August 31, 2004.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (j) | Manufacturing Facility. Manufacturing Facility shall mean OSG Norwichs manufacturing facility located in Norwich, NY.
| | --- | ------------------------------------------------------------------------------------------------------------------------



| | (k) | Manufacturing Price. Manufacturing Price shall mean the price set forth in the Price Exhibit provided that, notwithstanding anything to the contrary, the
Manufacturing Price shall at all times be equal to or lower than any price for the Product offered by OSG Norwich to a third party.
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (l) | Manufacturing Responsibilities Document MRD. The MRD shall be developed by a ViroPharma representative and signed by authorized ViroPharma and OSG Norwich
representatives.
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (m) | Minimum Yield. Minimum Yield shall be the yield initially determined in Section 4 below.
| | --- | ------------------------------------------------------------------------------------------



| | (n) | NDA. NDA shall mean the New Drug Application Number 50-606 and any subsequent submissions, supplements or amendments thereto.
| | --- | -------------------------------------------------------------------------------------------------------------------------------



| | (o) | PEG Specifications. PEG Specifications shall mean the specifications for testing the PEG set forth in the Quality Agreement.
| | --- | ------------------------------------------------------------------------------------------------------------------------------



| | (p) | Product. Product shall mean various presentations of the finished product containing Active Ingredient set forth in Specifications Exhibit attached in the Quality
Agreement and incorporated herein by reference known under the registered trademark Vancocin.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (q) | Product Trademark. Product Trademark shall mean Vancocin.
| | --- | -----------------------------------------------------------



| | (r) | Quality Agreement. The Quality Agreement shall be developed by a ViroPharma representative and signed by authorized ViroPharma and OSG Norwich representatives.
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (s) | Regulatory Approval. Regulatory Approval shall mean satisfaction of any and all applicable FDA registration and notification requirements.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------



| | (t) | Regulatory Approval Date. Regulatory Approval Date shall mean the date OSG Norwich receives all Regulatory Approvals necessary to Manufacture the Product pursuant
to the terms of this Project Agreement.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-4-



---

| | (u) | Specifications. Specifications shall mean the specifications for Manufacturing and testing the Product set forth in Specifications Exhibit.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------



| | (v) | Specifications Exhibit. Specifications Exhibit shall mean the exhibit to the Quality Agreement that sets for the specifications for Manufacturing and testing the
Product.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (w) | Territory. Territory shall mean the fifty (50) states and the District of Columbia and any territories and commonwealths constituting the United States of
America, including Puerto Rico.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | Development Activities.
| | -- | -----------------------

In order for OSG Norwich
to start the Manufacture of the Product for ViroPharma, it will be necessary that the activities listed in the Development Plan be completed. The responsibilities of each of OSG Norwich, Lilly and ViroPharma in relation to the Development Plan, and
the time frames for completion of the Development Plan, are also set forth in the Development Plan. Except as set forth on the attached Schedule of Exceptions, OSG Norwich represents that all activities set forth in the Development Plan required to
be completed by either OSG Norwich and/or Lilly on or prior to the Project Agreement Effective Date have been completed. [***] shall pay OSG Norwich the fees designated in the Price Exhibit under the heading Development Activity Costs due
following the Regulatory Approval Date ([***] Development Costs). OSG Norwich acknowledges that [***] shall be responsible for all fees designated in the Price Exhibit under the heading Development Activity Costs due and
owing prior to or as of the Regulatory Approval Date ([***] Development Costs, together with the [***] Development Costs, the Development Costs). OSG Norwich acknowledges that the Development Costs represent OSG
Norwichs entire compensation for performance of activities related to completion of the Development Plan. The parties agree to make commercially reasonable efforts to continue to complete the Development Plan in accordance with its terms.

OSG Norwich acknowledges that Lilly has agreed (i) to keep ViroPharma advised of all significant actions under the Lilly Project
Agreement, including, without limitation any deviation from the Lilly Project Agreement; (ii) to share information, consult with ViroPharma and include ViroPharma in material decisions, including decisions regarding the Development Plan; and
(iii) to amend the Lilly Project Agreement, subject to ViroPharmas approval, following ViroPharmas and OSGs entry into this Project Agreement such that the Lilly Project Agreement will be limited to the supply of products
identified therein for sale solely in [***] (the Lilly Agreements). OSG Norwich will use commercially reasonable efforts to ensure that Lilly complies with the Lilly Agreements.

OSG Norwich and ViroPharma acknowledge that certain development activities may be required in connection with API that is received from any source other
than Alpharma, Inc. (Third Party API). OSG Norwich and ViroPharma shall meet to discuss in good faith the parameters of such development activities, including timelines and cost. OSG Norwich shall not commence any work using the Third
Party API without ViroPharmas prior written approval.



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-5-



---

OSG Norwich and ViroPharma also agree to negotiate in good faith the terms and conditions under which OSG
Norwich shall undertake development activities in connection with process improvements (including but not limited to increasing the batch size) for the Manufacture of the Product.

Subject to the terms and conditions set forth herein, ViroPharma hereby grants to OSG a limited, non-exclusive, royalty free license under
ViroPharmas Patents and, ViroPharmas Know-How relating to the manufacture of Product (the Manufacturing Process Technology), with no right to sublicense or assign such licensed rights, solely for the purpose of performing
OSGs obligations under this Project Agreement, which are limited solely to manufacturing Product for and selling Product to ViroPharma, and any incidental purposes related thereto solely for the benefit of ViroPharma. OSG and ViroPharma
acknowledge and agree that (a) without limiting the generality of the foregoing, OSG shall not have any rights under the Manufacturing Process Technology to develop, manufacture or sell Product or any other product for any party other than
ViroPharma; (b) the Manufacturing Process Technology is, in whole and in part, the Confidential Information of ViroPharma; and (c) prior to and since November 9, 2004, Lilly has been providing the Manufacturing Process Technology to
OSG as a Representative of ViroPharma, and that it is the parties intention that, since such date, OSG has been operating solely in accordance with the license granted herein.



| | 3. | Equipment Purchase.
| | -- | -------------------

In order for OSG Norwich to
manufacture Product for ViroPharma, it will be necessary for OSG Norwich to purchase Equipment (as described below) required for the manufacturing process. OSG Norwich agrees to purchase and install the necessary Equipment. ViroPharma agrees to
reimburse OSG Norwich for all fees under the heading Capital Reimbursement due following the Regulatory Approval Date (VP Capital Reimbursement Fees). OSG Norwich acknowledges that Lilly shall be responsible for all fees under the
heading Capital Reimbursement due and owing prior to and as of the Regulatory Approval Date (Lilly Capital Reimbursement Fees). Except as set forth on the attached Schedule of Exceptions, OSG Norwich represents that all Lilly Capital
Reimbursement Fees due and owing as of the Project Agreement Effective Date have been paid in full.

In the event the Project Agreement is
assigned or terminated after the Regulatory Approval Date and prior to complete payment of the VP Capital Reimbursement Fees, the VP Capital Reimbursement Fees shall be paid to OSG Norwich through completion of the terms as listed in this Project
Agreement by the assignee or by ViroPharma in the event of termination prior to assignment. In the event the assignee fails to make payment, ViroPharma shall pay the remaining outstanding VP Capital Reimbursement Fees.

OSG Norwich shall maintain the Equipment in good working condition and in a manner consistent with industry practices and insured in the ordinary course
of business.

OSG Norwich shall inform ViroPharma in writing sixty (60) days prior to utilizing installed Equipment and capital for
manufacturing of any material other than Product,



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-6-



---

which use shall be additionally subject to Section 4 below. Manufacturing of penicillin,
cephalasporin, cytotoxic, or highly potent material on the installed Equipment and capital is not permitted. Validated cleaning methods shall be established for all other materials.

In the event the Project Agreement is terminated by OSG Norwich on or before the end of the Initial Term, or by ViroPharma at any time due to material
breach of this Project Agreement by OSG Norwich, [***] (collectively, the Equipment), shall be shipped to ViroPharma within [***] ([***]) days.

In the event that OSG Norwich does not want to renew the Project Agreement beyond the Initial Term, OSG Norwich shall a) return the Equipment to
ViroPharma if OSG Norwich has no product under contract utilizing the Equipment or b) reimburse to ViroPharma [***]% of the cost of an equivalent Equipment if OSG Norwich has product under contract utilizing the Equipment.

In the event that ViroPharma does not want to renew the Project Agreement beyond the Initial Term, OSG Norwich shall a) return the Equipment if OSG
Norwich has no product under contract utilizing the Equipment or b) retain title to the Equipment if OSG Norwich does have product under contract utilizing the Equipment.

Title to equipment and installed capital other than (a) the Equipment, and (b) any additional equipment used by OSG Norwich that is paid for by ViroPharma, will remain with OSG Norwich.



| | 4. | Manufacture of Product.
| | -- | -----------------------

Manufacture and
Purchase

Subject to the terms and conditions of this Project Agreement, the Agreement, the Quality Agreement and batch records approved
by ViroPharma, and the MRD, and beginning on the Commencement Date, OSG Norwich shall manufacture from Active Pharmaceutical Ingredient and supply to ViroPharma, and ViroPharma shall purchase from OSG Norwich, Product for commercial sale in the
Territory.

Except as provided below, during the period that OSG Norwichs Product Manufacturing Capacity (as defined
below) equals or exceeds ViroPharmas commercial requirements for finished cartons of the Product (as reflected in the first [***] Calendar Quarters of ViroPharmas most recent forecast for the Product delivered to OSG Norwich
pursuant to Section 4.1(b) of the Agreement, the Commercial Requirements), ViroPharma shall purchase at least [***]% of its Commercial Requirements for Product in the Territory during each such [***] Calendar Quarter
period exclusively from OSG Norwich, provided that,:



| | (a) | without regard to the Product Manufacturing Capacity:
| | --- | -----------------------------------------------------



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-7-



---

(i) if OSG Norwich is unable to meet the purchase orders of ViroPharma with respect to
quantity ordered, quality of the Product and time for delivery (assuming that such purchase orders meet the terms of this Project Agreement and the Master Agreement), then ViroPharma may obtain [***] Product from a third person;

(ii) OSG Norwich acknowledges that, at any time, ViroPharma shall have the right to qualify [***] third party suppliers to
manufacture the Product and that ViroPharma is permitted to purchase up to [***]% of its Commercial Requirements for Product in the Territory from such other third party suppliers; and

(iii) ViroPharma may purchase in excess of [***]% of its Commercial Requirements for the Product from Lilly through [***];
and

(b) during any period that OSG Norwichs Product Manufacturing Capacity is less than ViroPharmas Commercial
Requirements for the Product, ViroPharma may submit purchase orders for Product to, or otherwise obtain Product from, a third person in an amount not to exceed [***].

Prior to the Commencement Date, prior to each anniversary of the Commencement Date, and at any time (not to exceed [***] each calendar year) that
OSG Norwich, in good faith, reasonably determines that it has increased its Product Manufacturing Capacity by at least [***]%, ViroPharma and OSG Norwich shall meet and mutually agree in writing on the number of capsules of the Product that
OSG Norwich can Manufacture for ViroPharma during the [***] Calendar Quarter period following the Commencement Date, each anniversary thereof, or such other time described in the beginning of this paragraph, as applicable (the Number of
Capsules). If, within fifteen calendar days following the date that the parties meet to determine the Number of Capsules, the parties cannot agree on the Number of Capsules, the matter shall be submitted to arbitration. The parties shall
mutually agree on the selection of the arbitrator. If the parties cannot so agree within 5 business days after the expiration of the foregoing fifteen calendar day, each party shall select one arbitrator and the two arbitrators shall be instructed
to agree on a third arbitrator within five calendar days (the Selected Arbitrator). Within five business days after the appointment of the Selected Arbitrator, each of the parties shall submit in writing to the Selected Arbitrator its
calculation of the Number of Capsules and its reasoning in support thereof (each, a Written Proposal), and the Selected Arbitrator shall be required to make a final determination by choosing one of the parties proposed Number of
Capsules. The decision of the Selected Arbitrator in any such arbitration shall be final, binding and not appealable. Each Party shall pay its own expenses of arbitration and the expenses of the arbitrators shall be equally shared by the parties.
This arbitration provision shall be deemed to be self-executing, and in the event either party fails to submit timely its Written Proposal, then the Selected Arbitrator shall select the Number of Capsules stated in the other partys Written
Proposal.



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-8-



---

OSG Norwich:

(a) shall supply Product (including any other product containing the API) in the Territory exclusively to ViroPharma, except that OSG Norwich may continue to supply Product to Lilly to fulfill Lillys needs
outside of the Territory in [***];

(b) shall not supply Product, or any product containing the API, anywhere in the world to any
third person other than to (i) Lilly to fulfill Lillys needs in [***] or (ii) any assignee of Lillys rights and obligations in [***] under its Master Agreement with OSG Norwich dated March 13, 2003 (as
amended as of August 31, 2004) and its Project Agreement with OSG Norwich dated August 31, 2004 to fulfill such assignees needs in [***]; and

(c) may use the Equipment to manufacture a product for a third person (subject to the restrictions described in this Section 4 and in Section 3 above); provided that OSG Norwich shall, at all times, ensure
that ViroPharmas orders for Product are filled to the fullest extent of the capacity of the Equipment, and shall not reject or reschedule for later delivery (in whole or in part), any order for Product from ViroPharma, due to limitations or
restrictions that might otherwise arise relating to OSG Norwichs use of the Equipment for third parties.

OSG shall provide ViroPharma
in writing, within 5 business days after the end of each month, data describing the amount of PEG in OSGs possession at the end of the immediately preceding month.

Minimum Yield

The Minimum Yield for the first [***] lots (excluding validation lots) of 125mg
and 250mg presentations of the Product shall be [***]% of the theoretical yield (as described in the batch records for the Product) of finished cartons per batch (the Initial Minimum Yield). If the actual yield for the first
[***] lots (excluding validation lots) of 125mg and 250mg presentations of the Product is less than the Initial Minimum Yield, and if it determined that failure to meet Initial Minimum Yield is a direct result of OSG error, then OSG shall
reimburse to ViroPharma an amount equal to [***]. At ViroPharmas option, reimbursement shall be made to ViroPharma as a set off against invoices that ViroPharma owes OSG, or against future invoices related to the Product.

Following the manufacture of the first [***] lots (excluding validation lots) of 125mg and 250mg presentations of the Product 20, the Minimum
Yield will be established and agreed between ViroPharma and OSG, and thereafter the Minimum Yield will be subject to the provisions of section of 5.4 of the Agreement.



| | 5. | Manufacturing Price.
| | -- | --------------------

ViroPharma shall pay to OSG
Norwich, and OSG Norwich shall accept from ViroPharma, the Manufacturing Price designated in Price Exhibit as OSG Norwichs total compensation for Manufacture of Product, including all labor, materials, facilities, equipment, services, taxes,
overhead, and profit.



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-9-



---

The Manufacturing Price designated in Price Exhibit consists of two
(2) components: Materials Costs and Non-Materials Costs. The Materials Costs set forth on the Price Exhibit shall equal OSG Norwichs actual out-of-pocket costs to acquire the materials
described on the OSG Materials Exhibit attached hereto (Materials), and the Materials Costs described on the Price Exhibit shall include a handling fee equal to [***]% of such out-of pocket costs. The Materials Costs shall
initially be as set forth in the Price Exhibit, and shall remain firm for Product shipped prior to and during the [***] period of time after Commercial Manufacturing Initiation (such [***] period, and each subsequent [***]
period, a Commercial Manufacturing [***]). Following the first Commercial Manufacturing [***] hereunder, OSG Norwich may, in accordance with the procedure set forth below, notify ViroPharma [***] in each
Commercial Manufacturing [***] of any changes in the Manufacturing Price due to changes in Materials Costs, such increase in Materials Costs not to exceed in any year OSGs actual out-of-pocket costs to acquire the Materials plus a
handling fee equal to [***]% of such out-of pocket costs.

The Non-Materials Costs shall be all other components of the
Manufacturing Price other than the Materials Costs. The Non-Materials Costs shall initially be as set forth in the Price Exhibit, and shall remain firm for Product shipped prior to and during the [***] Commercial Manufacturing
[***] hereunder. Following the [***] Commercial Manufacturing [***] hereunder, OSG Norwich may, in accordance with the procedure set forth below, notify ViroPharma [***] in each Commercial Manufacturing [***]
of any changes in the Manufacturing Price due to changes in Non-Materials Costs, such increase in Non-Materials Costs not to exceed in any year the CPI-Adjusted Amount. The CPI Adjusted Amount shall be determined by multiplying the
then-current Non-Materials Costs by a fraction, (i) the numerator of which shall be equal to the difference between the Index for the calendar month immediately preceding the last month of the then-current Commercial Manufacturing [***],
less the Index for that same calendar month in the immediately preceding Commercial Manufacturing [***] (the Previous Index), and (ii) the denominator of which shall be equal to the Previous Index. For the purposes
hereof, the term Index means the Consumer Price Index published by the Bureau of Labor Statistics of the U.S. Department of Labor for all Urban Consumers (CPI-U)  U.S. All Items (1982-1984 = 100). In the event that the compilation
and/or publication of the Index shall be transferred to any other governmental department, bureau, or agency, or shall be discontinued, then the index most similar to the Index shall be used.

No changes to the Manufacturing Price shall be effective unless OSG Norwich delivers proper notice of any changes to the Materials Costs and/or
Non-Materials Costs, computed in accordance with the provisions set forth above and with accompanying documentation setting forth such computations in reasonable detail, to ViroPharma at least [***] ([***]) days prior to the expiration
of the then-current Commercial Manufacturing [***]. Changes in the Manufacturing Price will be effective for all Product shipped by OSG Norwich in the following Commercial Manufacturing [***].

Invoicing and payment shall be in United States dollars and shall follow the procedures set forth in the Agreement.



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-10-



---

The compensation for and development of ongoing stability testing is listed as Stability Costs in the
Price Exhibit (the Stability Costs). ViroPharma shall pay [***] Stability Costs due following the Regulatory Approval Date. OSG Norwich acknowledges that Lilly shall be responsible for [***] Stability Costs due and
owing prior to and as of the Regulatory Approval Date (Lilly Stability Costs). Except as set forth on the attached Schedule of Exceptions, OSG Norwich represents that all Lilly Stability Costs due and owing as of the Project Agreement
Effective Date have been paid in full.

The Stability Costs shall remain firm for stability services invoiced during the a [***] year
period of time after Commercial Manufacturing Initiation.

Upon ViroPharmas request, OSG Norwich shall provide to ViroPharma a written
estimate of any increase in cost in Manufacturing Product that may be caused by a change in the PEG Specifications. Any increase in cost experienced by OSG Norwich in Manufacturing Product for ViroPharma that is directly related to changes in the
PEG Specifications required by ViroPharma shall be passed on to ViroPharma.



| | 6. | Shelf Life and Storage Requirements.
| | -- | ------------------------------------

Subject at
all times to the limitations on OSG Norwichs obligations described in Section 18 of the Agreement (Force Majeure), Product shipped to ViroPharma or to other locations of ViroPharmas designation shall meet the following shelf life
and storage requirements:



|                      |  |                                                                                                                                                                                                                      
|--------------------- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Shelf Life:           |  | Minimum of [***] ([***]) to [***] ([***]) months remaining at time of shipment.                                                                                                                                      
|                      | 
|Storage Requirements: |  | The handling and storage conditions for finished Product are Controlled Room Temperature, which is equivalent to 15 to 30 C (59 to 86 F) (Note: refer to Quality Agreement for storage
conditions of Vancomycin HCl).



| | 7. | Term.
| | -- | -----

This Project Agreement shall be effective as
of the Project Agreement Effective Date and shall expire on the fifth (5th) anniversary of Commercial
Manufacturing Initiation. At the end of the Project Agreement Initial Term, this Project Agreement shall continue automatically for successive [***] periods under the same terms and conditions hereunder until terminated. This Project
Agreement may be terminated by ViroPharma at the expiration of the Project Agreement Initial Term or at the expiration of any renewal term upon not less than [***] ([***]) months prior written notice to OSG Norwich. OSG Norwich may
terminate this Project Agreement at the expiration of the Project Agreement Initial Term or at the expiration of any renewal term upon not less than [***] ([***]) months prior written notice to ViroPharma. In addition to the foregoing,
either Party may terminate this Project Agreement in the event of a material breach by the other Party of this Project Agreement, provided that the Party asserting such breach first serves written notice of the alleged breach on the offending Party
and such breach is not cured within [***] ([***]) days of said notice; provided further, however, that this Project Agreement shall not terminate in the event of a material breach pursuant to this Section 7



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-11-



---

unless, at the termination of such [***] ([***]) day period, the Party asserting such
breach notifies the other Party in writing of such termination due to a failure to cure the material breach.



| | 8. | Entire Agreement.
| | -- | -----------------

This Project Agreement, the
Agreement, the Quality Agreement, and the MRD, including the exhibits and other attachments hereto and thereto, contain the entire agreement between the parties relating to the subject hereof and supersedes all prior drafts or understanding, whether
written or oral, relating to the subject matter hereof.



| | 9. | Amendment.
| | -- | ----------

Except as otherwise provided herein,
this Project Agreement, including the exhibits and other attachments hereto, may be modified or amended only by written agreement of the Parties hereto signed by authorized representatives of the Parties.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-12-



---

IN WITNESS WHEREOF, the Parties have caused this Project Agreement to be executed and delivered on the date first set
forth above.



|                                  |  |                           
|--------------------------------- |  | --------------------------
|VIROPHARMA INCORPORATED          
|                                  | 
|By:                               |  | /s/ Michel de Rosen       
|Printed Name:                     |  | Michel de Rosen           
|Title:                            |  |                           
|                                 
|OSG NORWICH PHARMACEUTICALS, INC.
|                                  | 
|By:                               |  | /s/ Christopher R. Calhoun
|Printed Name:                     |  | Christopher R. Calhoun    
|Title:                            |  | President                 



-13-



---

PRICE EXHIBIT

PRODUCT:Vancocin capsules

MATERIALS:



| |  ̈ | ViroPharma Supplied: Vancomycin Hydrochloride API, and Polyethylene Glycol (PEG).
| | - | ---------------------------------------------------------------------------------



| |  ̈ | OSG Norwich Supplied: All other materials required for manufacturing and packaging.
| | - | -----------------------------------------------------------------------------------



|         |  |                                                                  
|-------- |  | -----------------------------------------------------------------
|TERMS:   |  | Net [***] days                                                   
|         | 
|FOB:     |  | [***]                                                            
|         | 
|PALLETS: |  | $[***]each for OSG Norwich supplied pallets used to ship Product.

MANUFACTURING PRICE:

Vancocin Capsules 125 mg and 250 mg:

A. For the first [***] ([***]) successful validations batches of each presentation of Product
manufactured hereunder, costs and pricing are as follows:



|                                                   |  |                                                |  |                                                   
|-------------------------------------------------- |  | ---------------------------------------------- |  | --------------------------------------------------
|Non-Materials Costs per finished carton of Product |  | Materials Costs per finished carton of Product |  | Manufacturing Price per finished carton of Product
|$[***]                                             |  | $[***]                                         |  | $[***]                                            

B. If additional Product is required by ViroPharma for commercial sale under this Project Agreement in excess of
the first [***] ([***]) successful validations batches of each presentation of Product referred to above, then costs and pricing are as follows:

1. 125 mg:



|                                                   |  |                                                |  |                                                   
|-------------------------------------------------- |  | ---------------------------------------------- |  | --------------------------------------------------
|Non-Materials Costs per finished carton of Product |  | Materials Costs per finished carton of Product |  | Manufacturing Price per finished carton of Product
|$[***]                                             |  | $[***]                                         |  | $[***]                                            

2. 250 mg:



|                                                   |  |                                                |  |                                                   
|-------------------------------------------------- |  | ---------------------------------------------- |  | --------------------------------------------------
|Non-Materials Costs per finished carton of Product |  | Materials Costs per finished carton of Product |  | Manufacturing Price per finished carton of Product
|$[***]                                             |  | $[***]                                         |  | $[***]                                            

---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-14-



---

For clarity, each finished carton of Product shall contains [***] blister packs of [***] capsules of
Product, and the total cost per finished carton of Product includes [***]. The Manufacturing Price per finished carton of Product shall at all times be [***].

DEVELOPMENT ACTIVITY COSTS

OSG Norwich acknowledges that Lilly shall reimburse OSG Norwich, and that ViroPharma
shall have no liability, for the actual manufacturing costs relating to project initiation, demonstration and validation lots, and all costs relating to technology transfer, manufacturing process validation, packaging validation and cleaning
validation, incurred prior to Regulatory Approval.

Development and Validation Stability Charges

Completion of stability tests for the initial time points for all development and validation lots are included in Process Qualification and IOQ charges. Additional
stability costs for Development Activities will be charged on a $[***] pull price. Stability charges for this Product shall be invoiced at the completion of stability testing and documentation. The following stability table outlines the project
stability requirements and estimated charges.

Development Lots: [***]

[***]

Validation
Lots[***]

[***]

CAPITAL REIMBURSEMENT:

OSG Norwich shall purchase the following equipment required to manufacture the Product.



|      |  |      |     
|----- |  | ---- | ----
|Type  |  | Cost |     
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|[***] |  | [    | ***]
|TOTAL |  | [    | ***]

---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-15-



---

OSG Norwich is financing the cost of this equipment at [***] percent annual rate over a [***]
([***]) year term. The total cost of the capital requirement and interest is $[***] (the Capital Reimbursement Amount). OSG Norwich shall be reimbursed by either Lilly or ViroPharma for the Capital Reimbursement Amount in
accordance with Section 3 by paying the following schedule of payments due [***]after receipt of invoice:



|      |  |       
|----- |  | ------
|Date  |  | Amount
|[***] |  |       

POST-APPROVAL COSTS

ViroPharma shall pay OSG for the activities described below to be conducted following the Regulatory Approval Date at the rates indicated below.

Reference Standard Management

OSG Norwich shall manage the reference standards for Third Party API at no
additional cost to ViroPharma.

Stability Costs:

Cost per Pull: $[***]. Pull is defined as testing and documenting results of required analytical methods as required in the Product Specification for one sample for one time point for each
condition.



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-16-



---

Stability Table: The following are the estimated requirements for the stability program for this
Product. Stability charges for this Product shall be invoiced at the time of the completion of stability testing and documentation.

Routine Pulls: [***] of each strength per year for a total of [***]per year

[***]

Non-routine Stability Request: In the event of a deviation, either party may request an additional stability study. OSG Norwich and
ViroPharma shall discuss in good faith the event leading to the request. In the event that the deviation is clearly the result of fault of OSG Norwich, OSG Norwich shall be responsible for costs associated for related stability pulls. In the event
that the cause of the deviation is not clearly due to the fault of OSG Norwich, then the parties shall discuss in good faith the responsibility of costs associated for related stability pulls.



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-17-



---

DEVELOPMENT PLAN EXHIBIT

Except as set forth on the attached Schedule of Exceptions, Lilly has previously supplied OSG Norwich with the following information [***]:



| | 1) | Process flow chart
| | -- | ------------------



| | 2) | Process flow document
| | -- | ---------------------



| | 3) | Development history reports
| | -- | ---------------------------



| | 4) | Existing stability protocols for drug product
| | -- | ---------------------------------------------



| | 5) | In-process control methods
| | -- | --------------------------



| | 6) | Master Formulas of Indianapolis registration stability lots with Alpharma vancomycin hydrochloride
| | -- | --------------------------------------------------------------------------------------------------



| | 7) | Raw material specifications
| | -- | ---------------------------



| | 8) | Raw material suppliers
| | -- | ----------------------



| | 9) | Drug product specifications
| | -- | ---------------------------



| | 10) | Health and safety information
| | --- | -----------------------------



| | 11) | Analytical Methods
| | --- | ------------------



| | 12) | Analytical Transfer Protocols
| | --- | -----------------------------



| | 13) | Cleaning Method Protocol
| | --- | ------------------------

OSG Norwich
has completed the following activities prior to start of validation[***]:

[***]

OSG Norwich will transfer the following methods prior to validation [***]:



|       |  |         
|------ |  | --------
|Method |  | Used For
|[***]  |  |         

---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-18-



---

[***]

OSG Norwich will manufacture the following type and number of lots for the described purpose:

[***]



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-19-



---

OSG Norwich will complete the following activities prior to technical transfer completion [***]:

 ̈[***]

 ̈[***]

 ̈[***]

 ̈[***]

 ̈[***]

---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-20-



---

SCHEDULE OF EXCEPTIONS

None



-21-



---

MATERIALS EXHIBIT

Provided by OSG Norwich:

[***]



---

|[***] | Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
|----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



-22-